Company / R&D per Share
Astria Therapeutics, Inc. R&D per Share History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$1.37
FY2024
5-year range
$1.37 / $8.37
FY2020-FY2024
Trend
-1.8%
vs FY2023
Sector context
#130 of 208
Health Care
What the data says
At $1.37, Astria Therapeutics, Inc.'s r&d per share ranks #130 of 208 in the Health Care sector. R&D per Share has fluctuated over the past 10 years, ranging from $1.37 in FY2024 to $8.62 in FY2017.
Based on SEC 10-K filings.
1.37 in FY2024 with a 5-year CAGR of -6.2%.
Declined from $2.34 to $1.37 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -7.6%
- 5-Year CAGR
- -6.2%
- 10-Year CAGR
- -
Sector benchmark
#130 of 208 in Health CareTop 62% of 208This company $1.37 Sector average $28.82
▼
-95.2% below sector average
Key checks
Key Insights
- In FY2024, r&d per share decreased 1.8% year-over-year.
- Ranks #130 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 5.45 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $1.37 | -1.8% |
| FY2023 | $1.40 | -40.3% |
| FY2022 | $2.34 | +34.5% |
| FY2021 | $1.74 | -79.2% |
| FY2020 | $8.37 | +342.4% |
| FY2019 | $1.89 | -43.9% |
| FY2018 | $3.37 | -60.9% |
| FY2017 | $8.62 | +449.5% |
| FY2016 | $1.57 | -45.2% |
| FY2015 | $2.86 | -92.3% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026